Results 1 - 10 of 1791

< 1 2 3 ... 179 180 >

• Sinha Nandita, Sen Srikanta. Predicting hERG activities of compounds from their 3D structures: Development and evaluation of a global descriptors based QSAR model, European Journal of Medicinal Chemistry, 2011

  [DOI: 10.1016/j.ejmech.2010.11.042]
  
• D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs, Psychopharmacology

  [DOI: 10.1007/BF02311185]
  
• Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology

  [DOI: 10.1007/BF02245606]
  
• Yamashita H; Yoda H; Kuroki N; Kuwabara M; Odagaki Y; Kazawa T; Toyoshima R; Maruki T. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine., Psychopharmacology

  [PubMed: 20820759]
  [DOI: 10.1007/s00213-010-2002-9]
  
• Wang YR; Yang YH; Lu CY; Lin SJ; Chen SH. Trace analysis of acetylcholinesterase inhibitors with antipsychotic drugs for Alzheimer's disease by capillary electrophoresis with on column field-amplified sample injection., Analytical and bioanalytical chemistry

  [PubMed: 23392410]
  [DOI: 10.1007/s00216-013-6767-7]
  
• McElroy SL; Guerdjikova AI; Mori N; Keck PE Jr. Psychopharmacologic treatment of eating disorders: emerging findings., Current psychiatry reports

  [PubMed: 25796197]
  [DOI: 10.1007/s11920-015-0573-1]
  
• Wobrock T; D'Amelio R; Falkai P. [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review]., Der Nervenarzt

  [PubMed: 17619840]
  [DOI: 10.1007/s00115-007-2310-4]
  
• Javelot H; Baratta A; Weiner L; Javelot T; Nonnenmacher C; Westphal JF; Messaoudi M. Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge., Pharmacy world & science : PWS

  [PubMed: 19039677]
  [DOI: 10.1007/s11096-008-9272-x]
  
• Hrdlicka M; Beranova I; Zamecnikova R; Urbanek T. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study., European child & adolescent psychiatry

  [DOI: 10.1007/s00787-007-0670-8]
  
• Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study., Psychopharmacology

  [DOI: 10.1007/s00213-016-4445-0]